Testosterone

The law firm of Pearson, Randall, & Schumacher is investigating potential lawsuits related to injuries caused by brand name testosterone therapy products such as Androgel®, Axiron®, Androderm®, Foresta® and Testim®.  Currently, there are multiple testosterone lawsuits related to testosterone therapy currently filed and consolidated in United States Federal District Court, Northern District of Illinois before the Honorable Judge Matthew F. Kennelly. If you have been potentially injured by a testosterone therapy replacement product please contact Pearson, Randall, & Schumacher at 612-767-7500 to investigate a potential testosterone therapy lawsuit.

Pharmaceutical companies promote testosterone replacement therapy as the way to increase muscle mass, sharpen memory and concentration, boost libido and increase energy level in aging men.  “Yet the health benefits of testosterone therapy for age-related decline in testosterone aren’t as clear as they may seem.” http://www.mayoclinic.org/healthy-living/sexual-health/in-depth/testosterone-therapy/art-20045728.htm

On January 31, 2014, the Federal Food and Drug Administration (FDA) generated a Drug Safety Communication entitled FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products.     In its safety announcement, the FDA stated that it was investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products.  The FDA went on to state that” “We have been monitoring this risk and decided to reassess this safety issue based on the recent publication of two separate studies that each suggest an increased risk of cardiovascular events among groups of men prescribed testosterone therapy.  http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm

At the time of the alert the FDA had not concluded that FDA-approved testosterone treatment increased the risk of stroke, heart attack or death but that the FDA was continuing to evaluate the available information, studies and data.  The FDA noted that patients should not stop taking prescribed testosterone products without first consulting with their health care professional.  http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm

On June 19, 2014 the FDA required manufacturers to include a general warning in the drug labeling of all approved testosterone products about the risk of the potential for venous blood clots.  The FDA said that “blood clots in the veins, also known as venous thromboembolism (VTE), include deep vein thrombosis (DVT) and pulmonary embolism (PE).”  The FDA required a change to drug labeling of all testosterone products to provide a more general warning regarding venous blood clots and to ensure the risk is described consistently in the labeling of all approved testosterone products.  http://www.fda.gov/Drugs/DrugSafety/ucm401746.htm

The law firm of Pearson, Randall, & Schumacher is currently investigating cases of men who were prescribed testosterone therapy and suffered a heart attack, stroke, deep vein thrombosis, pulmonary embolism or death while taking the prescribed testosterone.  If you experienced one or more of these serious medical events while taking or after taking testosterone replacement therapy you should call Pearson, Randall, & Schumacher to discuss your situation.